Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in Mice

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Abadie, Valérie ^a,b,c,e   Bonduelle, Olivia ^a,b,c   Duffy, Darragh ^a,b,c   Parizot, Christophe ^a,b,c   Verrier, Bernard ^d   Combadière, Béhazine ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; MODIFIED VACCINIA VIRUS ANKARA VACCINE; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINIA VACCINE; ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION; INNATE IMMUNITY; LYMPHOID ORGAN; MACROPHAGE; MOUSE; MYELOID DENDRITIC CELL; NEUTROPHIL; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; VACCINATION; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CROSS PRESENTATION; CYTOLOGY; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPH NODE; PHENOTYPE; TISSUE DISTRIBUTION; VACCINIA VIRUS;

MUS; VACCINIA VIRUS ANKARA; VARIOLA VIRUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; CROSS-PRIMING; FEMALE; IMMUNITY; IMMUNIZATION; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; LYMPH NODES; MICE; MICE, INBRED C57BL; MYELOID CELLS; PHENOTYPE; T-LYMPHOCYTES; TISSUE DISTRIBUTION; VACCINIA VIRUS;

EID: 77949536675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008159     Document Type: Article

References (48)

1. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, et al. (2003) Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100: 9458-9463.
2. Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, et al. (2003) Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 100: 217-222.
3. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, et al. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428: 182-185.
4. Wyatt LS, Earl PL, Eller LA, Moss B (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101: 4590-4595.
5. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, et al. (2005) Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339: 164-175.
6. Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO (2007) Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 25: 34-42.
7. Carroll MW, Moss B (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
8. Drexler I, Heller K, Wahren B, Erfle V, Sutter G (1998) Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 (Pt 2): 347-352.
9. Blanchard TJ, Alcami A, Andrea P, Smith GL (1998)Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 (Pt 5): 1159-1167.
10. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, et al. (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19: 3700-3709.
11. Puissant B, Combadiere B (2006) Keeping the memory of smallpox virus. Cell Mol Life Sci 63: 2249-2259.
12. Gomez CE, Najera JL, Krupa M, Esteban M (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97-120.
13. Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, et al. (2004) Distinct time effects of vaccination on long-term proliferative and IFN-gammaproducing T cell memory to smallpox in humans. J Exp Med 199: 1585-1593.
14. Amara RR, Nigam P, Sharma S, Liu J, Bostik V (2004) Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78: 3811-3816.
15. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
16. Seder RA, Darrah PA, Roederer M (2008) T cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
17. Estcourt MJ, Letourneau S, McMichael AJ, Hanke T (2005) Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol 35: 2532-2540.
18. Shen X, Wong SB, Buck CB, Zhang J, Siliciano RF (2002) Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol 169: 4222-4229.
19. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, et al. (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201: 95-104.
20. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R (2004) Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 1: 10.
21. Chahroudi A, Chavan R, Kozyr N, Waller EK, Silvestri G, et al. (2005) Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J Virol 79: 10397-10407.
22. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW (2002) Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol 3: 265-271.
23. Hickman HD, Takeda K, Skon CN, Murray FR, Hensley SE, et al. (2008) Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol 9: 155-165.
24. Iga M, Boissonnas A, Mahe B, Bonduelle O, Combadiere C, et al. (2007) Single CX3CL1-Ig DNA administration enhances T cell priming in vivo. Vaccine 25: 4554-4563.
25. Hamilton-Easton A, Eichelberger M (1995) Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice. J Virol 69: 6359-6366.
26. Usherwood EJ, Hogg TL, Woodland DL (1999) Enumeration of antigenpresenting cells in mice infected with Sendai virus. J Immunol 162: 3350-3355.
27. Pulendran B (2004) Modulating vaccine responses with dendritic cells and Tolllike receptors. Immunol Rev 199: 227-250.
28. Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, GonzalezAseguinolaza G, et al. (2007) Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 88: 2473-2478.
29. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, et al. (2005) Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106: 1843-1850.
30. Bonneau M, Epardaud M, Payot F, Niborski V, Thoulouze MI, et al. (2006) Migratory monocytes and granulocytes are major lymphatic carriers of Salmonella from tissue to draining lymph node. J Leukoc Biol 79: 268-276.
31. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J (1996) Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 70: 8301-8309.
32. Pozzi LA, Maciaszek JW, Rock KL (2005) Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol 175: 2071-2081.
33. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I (2007) Crosspriming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81: 11925-11936.
34. Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, et al. (2003) Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 301: 1925-1928.
35. Zhao X, Deak E, Soderberg K, Linehan M, Spezzano D, et al. (2003) Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J Exp Med 197: 153-162.
36. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, et al. (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19: 47-57.
37. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, et al. (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25: 153-162.
38. Mount AM, Smith CM, Kupresanin F, Stoermer K, Heath WR, et al. (2008) Multiple dendritic cell populations activate CD4+ T cells after viral stimulation. PLoS ONE 3: e1691. doi:10.1371/journal.pone.0001691.
39. Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, et al. (2009) Crosspresentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 10: 488-495.
40. Belz GT, Smith CM, Eichner D, Shortman K, Karupiah G, et al. (2004) Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 172: 1996-2000.
41. Bontkes HJ, Ruizendaal JJ, Schreurs MW, Kramer D, Meijer CJ, et al. (2005) Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors. Cell Oncol 27: 175-182.
42. Yoneyama H, Matsuno K, Toda E, Nishiwaki T, Matsuo N, et al. (2005) Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 202: 425-435.
43. Leon B, Lopez-Bravo M, Ardavin C (2007) Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26: 519-531.
44. Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7: 543-555.
45. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204: 1405-1416.
46. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, et al. (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9: 1131-1137.
47. Macatonia SE, Hsieh CS, Murphy KM, O'Garra A (1993) Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFNgamma production is IFN-gamma-dependent. Int Immunol 5: 1119-1128.
48. Cosma A, Buhler S, Nagaraj R, Staib C, Hammarin AL, et al. (2004) Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus. Clin Diagn Lab Immunol 11: 406-410.